STOCK TITAN

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

BioLineRx (BLRX) signed an agreement with Soleus Capital Management and its affiliates to sell future APHEXDA royalties for a one-time $5.6 million payment. Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. BioLineRx retains rights to potential commercial milestone payments and royalties attributable to periods before closing. The deal is expected to close on or about November 30, 2026.

BioLineRx plans to use the non-dilutive proceeds to support research and development, including GLIX1, and to make a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with that repayment, BioLineRx’s current $4 million minimum cash balance requirement will be eliminated. The GLIX1 Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts.

Loading...
Loading translation...
6 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.One-time $5.6 million payment from Soleus Capital Management and its affiliates provides non-dilutive funding under the signed agreement 1× market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Current $4 million minimum cash balance requirement will be eliminated in connection with the planned partial loan repayment
  • Minor point. Forward-looking: it has not happened yet and may not happen.Partial loan repayment to BlackRock EMEA Venture and Growth Lending is a planned use of proceeds
  • Minor point. Forward-looking: it has not happened yet and may not happen.GLIX1 clinical development is a planned use of proceeds; the Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts
  • Minor pointPotential commercial milestone payments under the Ayrmid Pharma license remain with BioLineRx
  • Minor pointRoyalties attributable to periods before closing remain with BioLineRx

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.14.4% royalty interest in future APHEXDA net sales will transfer from BioLineRx to Soleus at closing
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Closing remains pending and is expected on or about November 30, 2026

Key Figures

One-time payment: $5.6 million Royalty interest sold: 14.4% Royalty interest excluded: 3.6% +3 more
One-time payment
$5.6 million
Payment for BioLineRx's APHEXDA royalty interest
Royalty interest sold
14.4%
BioLineRx's interest in future APHEXDA net sales
Royalty interest excluded
3.6%
Original licensor's interest remains outside the transaction
Minimum cash balance requirement
currently $4 million
Requirement under the loan agreement will be eliminated with partial loan repayment
Expected transaction closing
on or about November 30, 2026
Expected closing date
GLIX1 dosing cohorts
Fourth of five planned dosing cohorts
Ongoing Phase 1/2a clinical trial

Historical Context

1 past event · Latest: Nov 16
1 event
  1. Nov 16

    clinical update

    24h Move
    -11.5%

    Fourth GLIX1 cohort dosing began, with no significant treatment-emergent adverse events observed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cxcr4 antagonist, autologous stem cell transplantation, pdac
3 terms
cxcr4 antagonist medical
"APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration"
A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.
autologous stem cell transplantation medical
"for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma"
A procedure that collects a patient’s own stem cells, stores them, and then returns them after intensive treatment that wipes out diseased or malfunctioning cells. Think of it like saving seeds before clearing a garden and replanting them afterward to restore growth. Investors watch this because demand, costs, and outcomes influence sales of related drugs, devices and services, reimbursement decisions, and the commercial potential of new therapies.
pdac medical
"including metastatic pancreatic cancer (PDAC)"
PDAC stands for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer that starts in the pancreas’s duct cells. It matters to investors because PDAC represents a large unmet medical need with high patient mortality, driving intense drug development, clinical trial activity and potential regulatory milestones—like a critical, hard-to-fix engine part whose failure creates urgent demand for effective solutions, affecting a company’s valuation and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -

- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts -

- BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid -

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.

BioLineRx Ltd. Logo

Under the terms of the agreement, Soleus will acquire BioLineRx's 14.4% royalty interest in future net sales of APHEXDA under the Company's existing license agreement with Ayrmid Pharma Ltd. ("Ayrmid"). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of the transaction.

"This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments," said Philip Serlin, Chief Executive Officer of BioLineRx. "Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our  shareholders."

"We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA," said Benjamin Lund, Partner at Soleus Capital. "We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement."

BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company's minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The transaction is expected to close on or about November 30, 2026.

About APHEXDA® (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.

About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

About Soleus Capital
Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately $3.5 billion in total assets under management as of June 30, 2026, Soleus Capital invests across the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure with hedge fund, private equity and structured credit vehicles.

Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the consummation and expected benefits of the royalty monetization transaction with Soleus Capital; BioLine's receipt and intended use of the transaction proceeds; the completion and expected effects of the partial repayment of BioLine's outstanding loan facility, including the elimination of the minimum cash balance requirement; the future commercial performance, market uptake and net sales of APHEXDA; potential future royalty and commercial milestone payments relating to APHEXDA; the ongoing Phase 1/2a clinical trial of GLIX1, including its enrollment, progress and the timing and results of any clinical readout; and BioLineRx's business strategy, financial position and financing requirements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receive adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

For BioLineRx:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-enters-into-5-6-million-royalty-monetization-transaction-with-soleus-capital-302943737.html

SOURCE BioLineRx Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will BioLineRx receive for its APHEXDA royalties, and what is it selling?

BioLineRx agreed to a one-time $5.6 million payment for its 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. Soleus Capital Management and its affiliates are the buyers.

Does the BioLineRx APHEXDA royalty deal include the original licensor’s share?

No. The deal excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide, which retains that interest.

Keep reading